# Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct02948998` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02948998](<https://clinicaltrials.gov/study/NCT02948998>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02948998

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

## Technical summary

Registry record NCT02948998. Randomized; no masking; primary purpose treatment. Start 2018-05-14 (anticipated); primary completion 2019-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 260 participants (planned count; ClinicalTrials.gov record NCT02948998, source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)
- Planned start: 2018-05-14 (anticipated) (ClinicalTrials.gov record NCT02948998, source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)
- Primary completion: 2019-10 (anticipated) (ClinicalTrials.gov record NCT02948998, source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)
- Completion: 2020-07 (anticipated) (ClinicalTrials.gov record NCT02948998, source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02948998, source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02948998-2018-05-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
- Condition: Hypertrophic Cardiomyopathy
- Condition: Fibrosis
- Intervention (Drug): Spironolactone
- Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER
- Collaborator: Ruijin Hospital
- Collaborator class: OTHER
- Collaborator: RenJi Hospital
- Collaborator class: OTHER
- Collaborator: Shanghai Jiao Tong University Affiliated Sixth People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-xinhua-hospital-shanghai-jiao-tong-university-school-of-9039af`)
- Registry lists this organization as a collaborator: Ruijin Hospital (`cardio:org-ruijin-hospital`)
- Registry lists this organization as a collaborator: RenJi Hospital (`cardio:org-renji-hospital`)

## Provenance

Content hash: 0ecf6bfbbccf9b7fc9feb45407dd891fb23cc68a1ba01f9dc764b5c597095866
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
